Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04322136Not ApplicableCompleted

AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion

Role: collaborator

NCT07059208Not ApplicableNot Yet Recruiting

Atrioventricular Nodal Ablation Versus Pulmonary Vein Isolation - Patient Centred Decisions

Role: lead

NCT06496516Not Yet Recruiting

Transperineal Ultrasound for Assessing and Predicting Response in Hospitalized Patients with a Flare of Ulcerative Colitis

Role: lead

NCT06035055Phase 4Unknown

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

Role: lead

NCT03267628Not ApplicableWithdrawn

Comparison of Intrathecal Morphine With the Quadratus Lumborum Type 2 Block for Post-operative Analgesia Following Elective Caesarean Section (QLBvITM Study)

Role: collaborator

All 5 trials loaded